Because almost all studies evaluating PPARα/γ-modulators have been performed on the DSS-induced colitis model (Supplementary Tables 1–2), we asked whether the PPARα/γ dual agonist PAR5359 can ameliorate colitis in this model. This evidence concerns the gene PPARA and colitis.